Here at HNVG we are very excited to be involved in the launch of a brand new lameness treatment from Boehringer Ingelheim and Global Stem cell Technology! It is a stem cell based product which offers a totally different way of treating lameness and is particularly targeted at young – middle aged horses with milder lameness in which it hopes to both resolve the lameness and improve future joint health. It is the first stem cell-based veterinary medicine to get marketing authorisation for treating equine degenerative joint disease.
Joint disease in horses is very common. Osteoarthritis, or degenerative joint disease (DJD), causes up to 60% of all lamenesses. DJD can be caused by general wear and tear, injury to the joint or developmental disorders such as bone chips (also known as OCD fragments). DJD involves ongoing damage to the joint cartilage along with changes in the bone and soft tissue of the joint.
Lameness caused by joint disease:
> Diminishes athletic performance
> Contributes to early retirement
> Affects quality of life
Goals of treatment:
> Interrupt the inflammatory cycle
> Restore a healthy joint environment
> Repair damage to the cartilage
Traditional treatments for DJD are focused on alleviating the pain and inflammation part of the disease cycle. Traditional approaches to joint disease include rest, steroid injections, hyaluronic acid injections, oral non-steroidal anti-inflammatory (NSAIDs), surgery and supplements.
Stem Cell Treatment
Stem cells belong to a new generation of disease modifying treatments which have only just become available. This treatment focuses on not just alleviating pain and inflammation but also addressing the underlying disease itself.
There is a unique licensed stem cell treatment now available with stem cells collected from donor horses. These stem cells have been induced to form cartilage cells.
To find out more information please contact the clinic on 01608 730085 or via email firstname.lastname@example.org or speak to one of our vets!Back to news